Lilly’s FDA approval is based on the QWINT Phase 3 programme, which evaluated Onswik in more than 3,400 adults with type 2 diabetes across four clinical trials.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.